Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Sells $7,161,390.50 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director David E. I. Pyott sold 32,450 shares of the business’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the sale, the director now owns 136 shares in the company, valued at $30,013.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Alnylam Pharmaceuticals Stock Down 1.6 %

NASDAQ:ALNY opened at $243.00 on Friday. The company has a market capitalization of $30.74 billion, a PE ratio of -90.67 and a beta of 0.30. The stock’s 50 day moving average price is $159.86 and its 200 day moving average price is $164.73. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $252.87.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The company had revenue of $494.33 million for the quarter, compared to analysts’ expectations of $428.01 million. During the same period in the prior year, the business earned ($1.40) EPS. The business’s quarterly revenue was up 54.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -3.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Envestnet Portfolio Solutions Inc. acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at $227,000. Envestnet Asset Management Inc. increased its stake in shares of Alnylam Pharmaceuticals by 30.4% during the third quarter. Envestnet Asset Management Inc. now owns 24,570 shares of the biopharmaceutical company’s stock worth $4,351,000 after acquiring an additional 5,727 shares during the period. Hsbc Holdings PLC raised its holdings in Alnylam Pharmaceuticals by 14.7% during the third quarter. Hsbc Holdings PLC now owns 35,185 shares of the biopharmaceutical company’s stock worth $6,230,000 after purchasing an additional 4,508 shares in the last quarter. Acadian Asset Management LLC raised its holdings in Alnylam Pharmaceuticals by 52.4% during the third quarter. Acadian Asset Management LLC now owns 904 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 311 shares in the last quarter. Finally, Northern Trust Corp lifted its position in Alnylam Pharmaceuticals by 3.3% in the third quarter. Northern Trust Corp now owns 797,700 shares of the biopharmaceutical company’s stock valued at $141,273,000 after purchasing an additional 25,230 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on ALNY. UBS Group upped their target price on shares of Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the stock a “buy” rating in a research note on Friday. BMO Capital Markets reaffirmed an “outperform” rating and set a $234.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, June 24th. TD Cowen lifted their target price on Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the company a “buy” rating in a report on Tuesday. HC Wainwright restated a “buy” rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, June 24th. Finally, William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, April 8th. Eight equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $247.09.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.